1. Agency EM (2008) Volume 9A of The Rules Governing Medicinal Products in the European Union—Guidelines on Pharmacovigilance for Medicinal Products for Human Use. http://ec.europa.eu/health/files/eudralex/vol-9/pdf/vol9a_09-2008_en.pdf
2. Augustin M, Glaeske G, Radtke MA, Christophers E, Reich K, Schaefer I (2010) Epidemiology and comorbidity of psoriasis in children. Br J Dermatol 162(3):633–636
3. Augustin M, Reich K, Glaeske G, Schaefer I, Radtke M (2010) Co-Morbidity and age-related prevalence of psoriasis—analysis of health insurance data in Germany. Acta Derm Venereol 90(2):147–151
4. Augustin M, Spehr C, Radtke MA, Boehncke WH, Luger T, Mrowietz U, Reusch M, Strömer K, Wozel G, Kiedrowski RV, Rustenbach SJ, Purwins S, Reich K (2014) German psoriasis registry PsoBest: objectives, methodology and baseline data. J Dtsch Dermatol Ges 12(1):48–57
5. Ahlehoff O, Skov L, Gislason G, Gniadecki R, Iversen L, Bryld LE, Lasthein S, Lindhardsen J, Kristensen SL, Torp-Pedersen C, Hansen PR (2014) Cardiovascular outcomes and systemic anti-inflammatory drugs in patients with severe psoriasis: 5-year follow-up of a Danish nationwide cohort. J Eur Acad Dermatol Venereol. doi: 10.1111/jdv.12768 [Epub ahead of print]